Takeda Pharmaceutical Company Ltd Confirmation of post-offer intention statements (0639Z)
08 Enero 2020 - 01:00AM
UK Regulatory
TIDM0RN3 TIDMTTM
RNS Number : 0639Z
Takeda Pharmaceutical Company Ltd
08 January 2020
Better Health, Brighter Future
News Release
THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE
REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND
MERGERS (THE "CODE"), WHICH, INTER ALIA, REQUIRES A PARTY TO AN
OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS
FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT
HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED
INTENTIONS
FOR IMMEDIATE RELEASE
Rule 19.6(c) confirmation of post-offer intention statements
Osaka, Japan, January 8, 2020 --- Takeda Pharmaceutical Company
Limited ("Takeda") announces that, further to the completion of its
recommended offer for the entire issued and to be issued ordinary
share capital of Shire plc ("Shire") on January 8, 2019, its board
of directors has duly confirmed in writing to The Panel on
Takeovers and Mergers in accordance with the requirements of Rule
19.6(c) of the Code that Takeda has complied with its post-offer
statements of intent made pursuant to Rules 2.7(c)(iv) and 24.2 of
the Code, as originally detailed in its announcement of 8 May 2018
and the Shire scheme document published on 12 November 2018.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
OUPGZGGMGNFGGZZ
(END) Dow Jones Newswires
January 08, 2020 02:00 ET (07:00 GMT)
Takeda Pharmaceutical (LSE:0RN3)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Takeda Pharmaceutical (LSE:0RN3)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024